This patient is receiving Ozurdex (dexamethasone 0.7%) intravitreal injections every 2 months to control macular edema from a branch retinal vein occlusion (BRVO).
The Ozurdex implant slowly releases the steroid and eventually totally absorbs, with the clinical effect lasting about 2 to 3 months. This Optos image shows 3 Ozurdex implants in various stages of their life cycles.
Learning Points:
In addition to Ozurdex, other possible treatment modalities for BRVO macular edema include anti-VEGF or triamcinolone injections, and macular laser photocoagulation.
